Department of Pharmacy, 71107Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Int J Biol Markers. 2022 Sep;37(3):249-259. doi: 10.1177/03936155221105521. Epub 2022 Jun 21.
Overall survival of non-small cell lung cancer (NSCLC) patients remains disappointingly low. The estrogen receptor (ER) was considered a promising therapeutic target for NSCLC. Numerous studies have linked expression of ERβ to lung cancer outcome. However, results are conflicting regarding the association of ERβ with surviving lung cancer. The aim of this meta-analysis was to evaluate the prognostic aspect of ERβ expression on survival among NSCLC patients. We performed a final analysis of prognostic value of overexpression ERβ on 3500 patients from 18 evaluable studies (from January 1, 2000 to May 1, 2021). The reference category is specified as low ERβ expression levels. Summarized hazard ratios were calculated. Our study showed that the pooled hazard ratios of ERβ overexpression for overall survival in NSCLC was 0.81 (95% confidence interval (CI): 0.64-1.02, = 0.07) by univariate analysis and 1.06 (95% CI: 0.83-1.36, = 0.63) by multivariate analysis. Pooled hazard ratio by univariate analysis in Asian studies was 0.73 (95%CI: 0.59-0.89, = 0.002). Pooled hazard ratio by univariate analysis was 0.75 (95% CI: 0.61-0.93, = 0.009) from seven studies reported for nuclear ERβ. No significant results were found in subgroups by multivariate analysis. No significant results were found in studies outside Asia or in studies reported for cytoplasmic ERβ. Our results suggested that expression of ERβ might not be a direct prognostic factor for NSCLC patients. More detailed prospective studies are needed to identify direct prognostic factors in these patients.
非小细胞肺癌（NSCLC）患者的总体生存率仍然令人失望。雌激素受体（ER）被认为是 NSCLC 的一个有前途的治疗靶点。许多研究将 ERβ 的表达与肺癌的结果联系起来。然而，关于 ERβ 与肺癌患者生存的关系，结果存在争议。本荟萃分析旨在评估 ERβ 表达对 NSCLC 患者生存的预后意义。我们对来自 18 项可评估研究的 3500 名患者（2000 年 1 月 1 日至 2021 年 5 月 1 日）进行了 ERβ 过表达预后价值的最终分析。参考类别指定为低 ERβ 表达水平。计算了汇总的危险比。我们的研究表明，通过单变量分析，ERβ 过表达对 NSCLC 总生存率的汇总危险比为 0.81（95%置信区间（CI）：0.64-1.02， = 0.07），通过多变量分析为 1.06（95% CI：0.83-1.36，= 0.63）。在亚洲研究中单变量分析的汇总危险比为 0.73（95%CI：0.59-0.89， = 0.002）。在报告核 ERβ 的 7 项研究中单变量分析的汇总危险比为 0.75（95% CI：0.61-0.93， = 0.009）。多变量分析的亚组未发现显著结果。在亚洲以外的研究或细胞质 ERβ 的研究中未发现显著结果。我们的结果表明，ERβ 的表达可能不是 NSCLC 患者的直接预后因素。需要进行更多详细的前瞻性研究以确定这些患者的直接预后因素。
